About TSRI
Research & Faculty
News & Publications
Scientific Calendars
Scripps Florida
PhD Program
Campus Services
Work at TSRI
TSRI in the Community
Giving to TSRI
Directory
Library
Contact
Site Map & Search
TSRI Home

Scientific Report 2008


Committee on the Neurobiology of Addictive Disorders




Neurobiology of Feeding, Motivation, and Stress


E.P. Zorrilla, L. Steardo,* A. Tabarin,** S. Iwasaki,*** É. Fekete, Y. Zhao, V. Sabino, P. Cottone, M. Brennan, J. Helfers

* University of Palermo, Palermo, Italy
** Université Victor Ségalen Bordeaux 2, Hopital du Haut-Lévêque, Pessac, France
*** Osaka City University Medical School, Osaka, Japan

We continue to study motivated behavior, with an emphasis on brain reward and stress neurocircuits that control food intake and appetitive behavior. In an ongoing collaboration with B. Conti and M. Sanchez-Alavez, Molecular and Integrative Neurosciences Department, we identified a regulatory role for the cytokine IL-18 in energy homeostasis. Male and female mice that lacked IL-18 overate and became obese in adulthood. Conversely, central or peripheral administration of IL-18 suppressed food intake in fasted wild-type mice without producing malaise. We also showed a metabolic function for IL-18. Female mice that lacked this cytokine had reduced energy expenditure, whereas administration of IL-18 reduced feed efficiency in fasted mice.

We also studied the hedonic control of food intake by using diet-cycling models. Intermittent access to palatable (i.e., highly preferred) food decreased the reinforcing efficacy and intake of a less preferred, but otherwise acceptable, food. Rats withdrawn from access to palatable food also had increased anxiety-like behavior and activation of stress-regulatory corticotropin-releasing factor (CRF) systems in the central nucleus of the amygdala, changes not detected when palatable food was available. Restoration of access to palatable food led to overeating. Administration of a CRF1 receptor antagonist blocked the increase in anxiety-like behavior and normalized the reinforcing efficacy of less preferred food while also blunting the observed changes in food intake. Despite eating no more overall than rats that were fed chow, diet-cycled rats ultimately became heavier and fatter, with elevated levels of adipokines associated with metabolic syndrome. Thus, intermittent access to palatable food had several effects that resembled those of addictive substances and which were reduced by CRF1 receptor antagonists.

We also combined pharmacologic and transgenic approaches to study the functional importance of urocortin-CRF2 receptor systems in the control of food intake. Local injection of urocortin 3 into the hypothalamus suppressed food intake via a CRF2 mechanism more potently than did administration into the hindbrain. Urocortin 3 prolonged satiety after a meal and slowed the rate and regularity of feeding within meals. Intracranial administration of urocortin 3 did not elicit anxiety-like or malaise-like behavior, whereas selective CRF1 receptor agonists did. Mutant mice lacking CRF2 had increased nocturnal food intake and abbreviated stress-induced anorexia, supporting a physiologic role for the CRF2 receptor in the control of food intake. Most recently, we showed that urocortin 2 is less potent, but has normal efficacy, in rats genetically vulnerable to diet-induced obesity compared with rats resistant to obesity. The ability of urocortin 2 to suppress high-fat food intake in obesity models is being evaluated.

Previously, in a collaborative study with K.D. Janda, Department of Chemistry, we showed that active immunization against the N-terminal residues of ghrelin, an acylated 28-residue stomach hormone that stimulates appetite and reduces lipid oxidation, slowed fat gain in rats proportional to the degree to which the rats generated antibodies that bind ghrelin. This research on active immunization against ghrelin continues, with a focus on the development of haptens, conjugated to feasible carrier proteins and designed not to elicit undesired cytotoxic T-cell responses, that can be commercialized. This work also involves further study of mechanism, efficacy, and safety. In addition, we recently found that acute administration of a catalytic antibody that facilitates degradation of ghrelin to its inactive des-acyl form increases energy expenditure in fasting mice and blunts refeeding after fasting. This finding suggests the practicality of passive administration approaches, which we are investigating by using several high-affinity, N terminally directed monoclonal antibodies.

Finally, we also found, partly in collaboration with G.F. Koob, Committee on the Neurobiology of Addictive Disorders, and A. Roberts, Molecular and Integrative Neurosciences Department, that previously known and novel small-molecule selective CRF1 receptor antagonists reduce anxiety-like behavior and blunt the excess drug self-administration that occurs in rodent models of alcohol, nicotine, and cocaine dependence.

Publications

Cottone, P., Sabino, V., Nagy, T.R., Coscina, D.V., Zorrilla, E.P. Feeding microstructure in diet-induced obesity susceptible versus resistant rats: central effects of urocortin 2. J. Physiol. 583:487, 2007.

Cottone, P., Sabino, V., Steardo, L., Zorrilla, E.P. Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology 33:524, 2008.

George, O., Ghozland, S., Azar, M.R., Cottone, P., Zorrilla, E.P., Parsons, L.H., O'Dell, L.E., Richardson, H.N., Koob, G.F. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc. Natl. Acad. Sci. U. S. A. 104:17198, 2007.

Lu, X., Ross, B., Sanchez-Alavez, M., Zorrilla, E.P., Bartfai, T. Phenotypic analysis of GalR2 knockout mice in anxiety and depression-related behavioral tests. Neuropeptides 42:387, 2008.

Richardson, H.N., Zhao, Y., Fekete, É.M., Funk, C.K., Wirsching, P., Janda, K.D., Zorrilla, E.P., Koob, G.F. MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol. Biochem. Behav. 88:497, 2008.

Specio, S.E., Wee, S., O'Dell, L.E., Boutrel, B., Zorrilla, E.P., Koob, G.F. CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berl). 196:473, 2008.

Tabarin, A., Diz-Chaves, Y., Consoli, D., Monsaingeon, M., Bale, T.L., Culler, M.D., Datta, R., Drago, F., Vale, W.W., Koob, G.F., Zorrilla, E.P., Contarino, A. Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis. Eur. J. Neurosci. 26:2303, 2007.

Zhao, Y., Valdez, G.R., Fekete, É.M., Rivier, J.E., Vale, W.W., Rice, K.C., Weiss, F., Zorrilla, E.P. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J. Pharmacol. Exp. Ther. 323:846, 2007.

Zhao, Y., Weiss, F., Zorrilla, E.P. Remission and resurgence of anxiety-like behavior across protracted withdrawal stages in ethanol-dependent rats. Alcohol. Clin. Exp. Res. 31:1505, 2007.

Zorrilla, E.P., Koob, G.F. Peptides. In: Encyclopedia of Stress, 2nd ed. Fink, H. (Ed.). Academic Press, Burlington, MA, 2007, Vol. 3, p. 91.

Zorrilla, E.P., Sanchez-Alavez, M., Sugama, S., Brennan, M., Fernandez, R., Bartfai, T., Conti, B. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl. Acad. Sci. U. S. A. 104:11097, 2007.

Zorrilla, E.P., Zhao, Y., Koob, G.F. Anti-CRF. In: Encyclopedia of Stress, 2nd ed. Fink, H. (Ed.). Academic Press, Burlington, MA, 2007, Vol. 1, p. 206.

 

Eric Zorilla, Ph.D.
Assistant Professor



Committee on the Neurobiology of Addictive Disorders

Scientific Report Home